NASDAQ:DNLI - Denali Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $80.86
  • Forecasted Upside: 11.17 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1 (-1.36%)

This chart shows the closing price for DNLI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Denali Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DNLI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DNLI

Analyst Price Target is $80.86
▲ +11.17% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Denali Therapeutics in the last 3 months. The average price target is $80.86, with a high forecast of $105.00 and a low forecast of $50.00. The average price target represents a 11.17% upside from the last price of $72.73.

This chart shows the closing price for DNLI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 investment analysts is to buy stock in Denali Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2021UBS GroupInitiated CoverageBuy$70.00High
3/4/2021HC WainwrightBoost Price TargetBuy$80.00 ➝ $95.00High
2/26/2021HC WainwrightReiterated RatingBuy$80.00 ➝ $95.00High
2/10/2021Cantor FitzgeraldUpgradeNeutral ➝ Overweight$105.00Low
1/8/2021JPMorgan Chase & Co.Initiated CoveragePositiveMedium
12/16/2020Morgan StanleyBoost Price TargetOverweight$75.00 ➝ $100.00High
11/11/2020JPMorgan Chase & Co.Boost Price TargetPositive ➝ Overweight$45.00 ➝ $65.00High
11/11/2020Morgan StanleyBoost Price TargetOverweight$45.00 ➝ $75.00High
11/10/2020The Goldman Sachs GroupBoost Price TargetPositive ➝ Buy$61.00 ➝ $81.00Low
11/6/2020HC WainwrightBoost Price TargetBuy$45.00 ➝ $65.00Medium
10/16/2020WedbushBoost Price TargetPositive ➝ Outperform$39.00 ➝ $50.00High
10/16/2020BTIG ResearchDowngradeBuy ➝ NeutralHigh
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00High
8/24/2020Morgan StanleyBoost Price TargetOverweight$28.00 ➝ $45.00Medium
8/20/2020HC WainwrightReiterated RatingBuy$28.00 ➝ $45.00Medium
8/10/2020WedbushReiterated RatingOutperformMedium
5/13/2020NomuraReiterated RatingBuy$35.00Low
4/15/2020Morgan StanleyLower Price TargetOverweight$30.00 ➝ $28.00High
3/18/2020Cantor FitzgeraldReiterated RatingNeutralMedium
3/13/2020Evercore ISIUpgradeIn-Line ➝ Outperform$20.00High
3/9/2020Nomura SecuritiesReiterated RatingBuy$35.00Low
2/28/2020WedbushUpgradeNeutral ➝ Outperform$24.00Low
2/24/2020Jefferies Financial GroupInitiated CoverageBuy$35.00High
2/18/2020Stifel NicolausInitiated CoverageHold$26.00Low
1/26/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$20.00 ➝ $37.00High
12/20/2019HC WainwrightReiterated RatingBuy$28.00Medium
9/25/2019WedbushInitiated CoverageNeutral$19.00 ➝ $19.00High
9/13/2019Nomura SecuritiesInitiated CoverageBuy$35.00High
8/9/2019Morgan StanleySet Price TargetBuy$32.00Low
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$30.00High
8/8/2019HC WainwrightReiterated RatingBuyMedium
7/15/2019HC WainwrightSet Price TargetBuy$28.00High
6/26/2019HC WainwrightInitiated CoverageBuy ➝ Buy$28.00Medium
1/29/2019Cantor FitzgeraldDowngradeOverweight ➝ Neutral$25.00High
12/7/2018Cantor FitzgeraldReiterated RatingBuy$25.00High
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$25.00High
11/12/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$26.00Low
1/2/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$23.00Medium
1/2/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ NeutralHigh
1/2/2018Morgan StanleyInitiated CoverageOverweight ➝ Overweight$25.00High
1/2/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$24.00High
(Data available from 6/22/2016 forward)
Denali Therapeutics logo
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $72.73
Low: $72.05
High: $74.48

50 Day Range

MA: $61.40
Low: $51.17
High: $75.06

52 Week Range

Now: $72.73
Low: $22.36
High: $93.94


944,729 shs

Average Volume

581,033 shs

Market Capitalization

$8.81 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Denali Therapeutics?

The following equities research analysts have issued stock ratings on Denali Therapeutics in the last year: BTIG Research, Cantor Fitzgerald, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for DNLI.

What is the current price target for Denali Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Denali Therapeutics in the last year. Their average twelve-month price target is $80.86, suggesting a possible upside of 11.2%. Cantor Fitzgerald has the highest price target set, predicting DNLI will reach $105.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $50.00 for Denali Therapeutics in the next year.
View the latest price targets for DNLI.

What is the current consensus analyst rating for Denali Therapeutics?

Denali Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DNLI will outperform the market and that investors should add to their positions of Denali Therapeutics.
View the latest ratings for DNLI.

What other companies compete with Denali Therapeutics?

How do I contact Denali Therapeutics' investor relations team?

Denali Therapeutics' physical mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-866-8548. The official website for Denali Therapeutics is